<?xml version='1.0' encoding='utf-8'?>
<document id="27558866"><sentence text="An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator."><entity charOffset="3-13" id="DDI-PubMed.27558866.s1.e0" text="S-warfarin" /><entity charOffset="99-109" id="DDI-PubMed.27558866.s1.e1" text="amino acid" /><pair ddi="false" e1="DDI-PubMed.27558866.s1.e0" e2="DDI-PubMed.27558866.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27558866.s1.e0" e2="DDI-PubMed.27558866.s1.e1" /></sentence><sentence text="AZD1981 is an orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) receptor antagonist progressed to phase II trials for the treatment of allergic asthma" /><sentence text=" Previously performed in vitro human hepatocyte incubations identified N-deacetylated AZD1981 as a primary metabolite" /><sentence text=" We report on metabolite exposure from a clinical excretion balance, on in vitro studies performed to determine the likelihood of a metabolite-dependent drug-drug interaction (DDI) and on a clinical warfarin DDI study" /><sentence text=" The aim was to demonstrate that N-deacetylated AZD1981 is responsible for the observed interaction" /><sentence text="" /><sentence text="The excretion and biotransformation of [14 C]-AZD1981 were studied in healthy male volunteers, and subsequently in vitro cytochrome P450 (CYP) inhibition and hepatocyte uptake investigations were carried out with metabolites and the parent drug" /><sentence text=" A clinical DDI study using coadministered twice-daily 100 mg and 400 mg AZD1981 with 25 mg warfarin was performed" /><sentence text="" /><sentence text="The excretion balance study showed N-deacetylated AZD1981 to be the most abundant metabolite present in plasma" /><sentence text=" In vitro data revealed the metabolite to be a weak CYP2C9 time-dependent inhibitor, subject to more active hepatic uptake than the parent molecule" /><sentence text=" Clinically, the S-warfarin area under the plasma concentration-time curve increased, on average, 1"><entity charOffset="17-27" id="DDI-PubMed.27558866.s12.e0" text="S-warfarin" /></sentence><sentence text="4-fold [95% confidence interval (CI) 1" /><sentence text="22, 1" /><sentence text="50] and 2" /><sentence text="4-fold (95% CI 2" /><sentence text="11, 2" /><sentence text="64) after 100 mg (n = 13) and 400 mg (n = 11) AZD1981 administration, respectively" /><sentence text=" In vitro CYP inhibition and hepatocyte uptake data were used to explain the interaction" /><sentence text="" /><sentence text="N-deacetylated AZD1981 can be added to the small list of drug metabolites reported as sole contributors to clinical drug-drug interactions, with weak time-dependent inhibition exacerbated by efficient hepatic uptake being the cause" /><sentence text="" /></document>